Search results
12 paź 2022 · Targeted therapy may include the following: conventional molecular targeted agents, such as small molecule inhibitors or antibodies that specifically inhibit signal transduction pathways involved...
- Full Size Table
Full Size Table - Molecular targeted therapy for anticancer...
- Full Size Image
Full Size Image - Molecular targeted therapy for anticancer...
- Metrics
Metrics - Molecular targeted therapy for anticancer...
- RSS Feed
Experimental & Molecular Medicine (EMM) is Korea's first...
- Sign up for Alerts
Sign up for Alerts - Molecular targeted therapy for...
- Press Releases
On this page. Latest corporate press releases; Springer...
- Full Size Table
Anticancer drug, any drug that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones.
7 lut 2022 · Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
31 maj 2021 · Over the past two decades, there has been a tremendous shift in cancer treatment, from broad-spectrum cytotoxic drugs to targeted drugs. 1 Compared with traditional chemotherapy drugs, targeted...
In this study, we collected and analyzed 150 anticancer drugs approved by the US Food and Drug Administration (FDA). Based on drug mechanism of action, these agents are divided into two groups: 61 cytotoxic-based drugs and 89 target-based drugs.
1 lip 2023 · Methotrexate is an anti-inflammatory molecule and is hence used as a medication for many other inflammatory diseases, like rheumatoid arthritis and extreme psoriasis, apart from various cancer types. A detailed description of common antimetabolites is comprehensively provided in Table 1.
17 gru 2020 · Here, we discuss recent mechanistic progress on the main immunomodulatory effects of US Food and Drug Administration (FDA)-approved and experimental targeted anticancer agents as we identify potential avenues to combine such agents with immunotherapy toward superior clinical efficacy.
